CO6362022A2 - Anticuerpos completamente humanos contra n-cadherina - Google Patents

Anticuerpos completamente humanos contra n-cadherina

Info

Publication number
CO6362022A2
CO6362022A2 CO11070983A CO11070983A CO6362022A2 CO 6362022 A2 CO6362022 A2 CO 6362022A2 CO 11070983 A CO11070983 A CO 11070983A CO 11070983 A CO11070983 A CO 11070983A CO 6362022 A2 CO6362022 A2 CO 6362022A2
Authority
CO
Colombia
Prior art keywords
cadherin
antibodies
cadherine
human antibodies
fragments
Prior art date
Application number
CO11070983A
Other languages
English (en)
Inventor
Robert Reiter
Eric Lepin
Anna M Wu
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CO6362022A2 publication Critical patent/CO6362022A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)

Abstract

La presente solicitud de patente provee anticuerpos y sus fragmentos, que incluyen anticuerpos completamente humanos y sus fragmentos, que son capaces de unirse a un dominio extracelular de N-cadherina. Los anticuerpos son útiles en el diagnóstico y en el tratamiento de cánceres que expresan o sobreexpresan N-cadherina. Por ejemplo, la solicitud de patente provee anticuerpos monoclonales, o fragmentos de ellos, que son capaces de unirse a los dominios extracelulares 1-3- de N-cadherina y que son útiles en el diagnóstico o el tratamiento de un cáncer de próstata o de vejiga humano que expresa o sobre expresa N-cadherina.
CO11070983A 2008-11-10 2011-06-08 Anticuerpos completamente humanos contra n-cadherina CO6362022A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11304208P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
CO6362022A2 true CO6362022A2 (es) 2012-01-20

Family

ID=42153647

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11070983A CO6362022A2 (es) 2008-11-10 2011-06-08 Anticuerpos completamente humanos contra n-cadherina

Country Status (13)

Country Link
US (2) US8703920B2 (es)
EP (1) EP2356145A4 (es)
JP (1) JP2012508027A (es)
KR (1) KR20110084309A (es)
CN (1) CN102300873A (es)
AU (1) AU2009313239A1 (es)
BR (1) BRPI0921457A2 (es)
CA (1) CA2743122A1 (es)
CO (1) CO6362022A2 (es)
IL (1) IL212795A0 (es)
MX (1) MX2011004945A (es)
RU (1) RU2011123655A (es)
WO (1) WO2010054377A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124281A2 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US20090130108A1 (en) * 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
US8663635B2 (en) * 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
GB201119089D0 (en) 2011-11-04 2011-12-21 Isis Innovation Treatment of musculoskeletal fibroproliferative disorders
EP2830659A1 (en) 2012-03-27 2015-02-04 Novartis AG Treatment of fibrosis
KR101899016B1 (ko) * 2014-08-21 2018-09-14 존슨 컨트롤스 테크놀러지 컴퍼니 배터리 모니터링 시스템
WO2018226795A1 (en) * 2017-06-06 2018-12-13 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof
WO2022237874A1 (en) * 2021-05-13 2022-11-17 Wuxi Biologics (Shanghai) Co., Ltd. Antibody conjugate comprising anti-p-cadherin antibody and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889157A (en) 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
AU2004242845B2 (en) * 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
EP1786463A4 (en) * 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20090130108A1 (en) 2006-03-21 2009-05-21 The Regents Of The University Of California N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2009124281A2 (en) 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin

Also Published As

Publication number Publication date
US20100233170A1 (en) 2010-09-16
KR20110084309A (ko) 2011-07-21
WO2010054377A9 (en) 2011-02-03
RU2011123655A (ru) 2012-12-20
CA2743122A1 (en) 2010-05-14
EP2356145A4 (en) 2012-07-18
WO2010054377A3 (en) 2010-09-16
EP2356145A2 (en) 2011-08-17
JP2012508027A (ja) 2012-04-05
MX2011004945A (es) 2011-11-01
AU2009313239A1 (en) 2011-07-07
CN102300873A (zh) 2011-12-28
BRPI0921457A2 (pt) 2016-01-12
WO2010054377A2 (en) 2010-05-14
US8703920B2 (en) 2014-04-22
US20140017240A1 (en) 2014-01-16
IL212795A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CO6362022A2 (es) Anticuerpos completamente humanos contra n-cadherina
CY1122816T1 (el) Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
UY32061A (es) Anticuerpos humanos para rankl humano
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
ECSP12011885A (es) Inmunoglobulinas con dominio variable dual
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
UY35468A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BRPI0719202A2 (pt) Diagnóstico e tratamento de câncer usando anticorpo antiereg
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
DK3423496T3 (da) Ikke-antagonistiske antistoffer rettet mod alfakæden i IL7-receptorens ekstracellulære domæne og anvendelse deraf i kræftbehandling
NZ607588A (en) Antibodies against human TWEAK and uses thereof
AR071304A1 (es) Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
CL2008003525A1 (es) Conjugado de anticuerpo monoclonal humano anti-rg1 o una porcion de union a antigeno del mismo con moleculas asociadas, composicion que lo comprende; metodo in vitro para inhibir el crecimiento de una celula tumoral que expresa rg-1; uso de dicho conjugado para tratar el cancer

Legal Events

Date Code Title Description
FA Application withdrawn